98 related articles for article (PubMed ID: 33107092)
1. Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA.
Deshpande S; Tytarenko RG; Wang Y; Boyle EM; Ashby C; Schinke CD; Thanendrarajan S; Zangari M; Zhan F; Davies FE; Morgan GJ; van Rhee F; Walker BA
Eur J Haematol; 2021 Feb; 106(2):230-240. PubMed ID: 33107092
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study.
Quivoron C; Michot JM; Danu A; Lecourt H; Saada V; Saleh K; Vergé V; Cotteret S; Bernard OA; Ribrag V
Leuk Lymphoma; 2024 Jun; 65(6):789-799. PubMed ID: 38433500
[TBL] [Abstract][Full Text] [Related]
3. Monitoring mutant KRAS in plasma cell-free DNA can predict disease progression in a patient with multiple myeloma: A case report.
Yamamoto M; Shindo M; Funayama T; Sumi C; Saito T; Toki Y; Hatayama M; Ono Y; Sato K; Mizukami Y; Okumura T
Clin Chim Acta; 2023 Nov; 551():117590. PubMed ID: 37837907
[TBL] [Abstract][Full Text] [Related]
4. Cell-free DNA for genomic profiling and minimal residual disease monitoring in Myeloma- are we there yet?
Thakral D; Das N; Basnal A; Gupta R
Am J Blood Res; 2020; 10(3):26-45. PubMed ID: 32685257
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies.
Sandecka V; Popkova T; Stork M; Maisnar V; Minarik J; Jungova A; Pavlicek P; Stejskal L; Pospisilova L; Heindorfer A; Obernauerova J; Gregora E; Sykora M; Ullrychova J; Wrobel M; Kessler P; Jelinek T; Kunovszki P; Bathija S; Gros B; Wilbertz S; Cai Q; Lam A; Spicka I
Blood Cancer J; 2023 Sep; 13(1):153. PubMed ID: 37752128
[TBL] [Abstract][Full Text] [Related]
6. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.
Medina-Herrera A; Vazquez I; Cuenca I; Rosa-Rosa JM; Ariceta B; Jimenez C; Fernandez-Mercado M; Larrayoz MJ; Gutierrez NC; Fernandez-Guijarro M; Gonzalez-Calle V; Rodriguez-Otero P; Oriol A; Rosiñol L; Alegre A; Escalante F; De La Rubia J; Teruel AI; De Arriba F; Hernandez MT; Lopez-Jimenez J; Ocio EM; Puig N; Paiva B; Lahuerta JJ; Bladé J; San Miguel JF; Mateos MV; Martinez-Lopez J; Calasanz MJ; Garcia-Sanz R;
Blood Cancer J; 2024 Apr; 14(1):74. PubMed ID: 38684670
[TBL] [Abstract][Full Text] [Related]
7. Smoldering multiple myeloma: taking the narrow over the wide path?
Avet-Loiseau H; Bahlis NJ
Blood; 2024 May; 143(20):2025-2028. PubMed ID: 38427775
[TBL] [Abstract][Full Text] [Related]
8. Liquid biopsies for multiple myeloma in a time of precision medicine.
Ferreira B; Caetano J; Barahona F; Lopes R; Carneiro E; Costa-Silva B; João C
J Mol Med (Berl); 2020 Apr; 98(4):513-525. PubMed ID: 32246161
[TBL] [Abstract][Full Text] [Related]
9. The use of cell free DNA (cfDNA) for mutational screening of multiple myeloma.
Marivel AJ; Ma Y; Becker TM; Verma A; Trieu S; Roberts TL; Ling SCW
Leuk Res Rep; 2023; 20():100393. PubMed ID: 37908506
[TBL] [Abstract][Full Text] [Related]
10. A Novel Tissue-Free Method to Estimate Tumor-Derived Cell-Free DNA Quantity Using Tumor Methylation Patterns.
Melton CA; Freese P; Zhou Y; Shenoy A; Bagaria S; Chang C; Kuo CC; Scott E; Srinivasan S; Cann G; Roychowdhury-Saha M; Chang PY; Singh AH
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201510
[TBL] [Abstract][Full Text] [Related]
11. Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma.
Maura F; Landgren O; Morgan GJ
Clin Cancer Res; 2021 Jan; 27(1):15-23. PubMed ID: 32759358
[TBL] [Abstract][Full Text] [Related]
12. Differential and limited expression of mutant alleles in multiple myeloma.
Rashid NU; Sperling AS; Bolli N; Wedge DC; Van Loo P; Tai YT; Shammas MA; Fulciniti M; Samur MK; Richardson PG; Magrangeas F; Minvielle S; Futreal PA; Anderson KC; Avet-Loiseau H; Campbell PJ; Parmigiani G; Munshi NC
Blood; 2014 Nov; 124(20):3110-7. PubMed ID: 25237203
[TBL] [Abstract][Full Text] [Related]
13. Everyday living with pain - reported by patients with multiple myeloma.
Jespersen E; Nielsen LK; Larsen RF; Möller S; Jarlbæk L
Scand J Pain; 2021 Jan; 21(1):127-134. PubMed ID: 33108340
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapeutic and Targeted Approaches in Multiple Myeloma.
Nadeem O; Tai YT; Anderson KC
Immunotargets Ther; 2020; 9():201-215. PubMed ID: 33117743
[TBL] [Abstract][Full Text] [Related]
15. Isatuximab for the treatment of relapsed/refractory multiple myeloma.
Richardson PG; Beksaç M; Špička I; Mikhael J
Expert Opin Biol Ther; 2020 Dec; 20(12):1395-1404. PubMed ID: 33111607
[TBL] [Abstract][Full Text] [Related]
16. Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy.
Walker ZJ; Idler BM; Davis LN; Stevens BM; VanWyngarden MJ; Ohlstrom D; Bearrows SC; Hammes A; Smith CA; Jordan CT; Mark TM; Forsberg PA; Sherbenou DW
Clin Cancer Res; 2021 Feb; 27(3):819-830. PubMed ID: 33109736
[TBL] [Abstract][Full Text] [Related]
17. Disparities in treatment patterns and outcomes among younger and older adults with newly diagnosed multiple myeloma: A population-based study.
Mian HS; Seow H; Wildes TM; Kouroukis CT; Pond GR; Sivapathasundaram B; Sussman J
J Geriatr Oncol; 2021 May; 12(4):508-514. PubMed ID: 33109484
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of CD200 expression in newly diagnosed multiple myeloma patients and dynamic changing during treatment.
Shi Q; Wu C; Han W; Zhao S; Wu Y; Jin Y; Qu X; Li J; Zhang R; Chen L
Leuk Lymphoma; 2021 Mar; 62(3):709-715. PubMed ID: 33108911
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
Danziger SA; McConnell M; Gockley J; Young MH; Rosenthal A; Schmitz F; Reiss DJ; Farmer P; Alapat DV; Singh A; Ashby C; Bauer M; Ren Y; Smith K; Couto SS; van Rhee F; Davies F; Zangari M; Petty N; Orlowski RZ; Dhodapkar MV; Copeland WB; Fox B; Hoering A; Fitch A; Newhall K; Barlogie B; Trotter MWB; Hershberg RM; Walker BA; Dervan AP; Ratushny AV; Morgan GJ
PLoS Med; 2020 Nov; 17(11):e1003323. PubMed ID: 33147277
[TBL] [Abstract][Full Text] [Related]
20. Putative Origins of Cell-Free DNA in Humans: A Review of Active and Passive Nucleic Acid Release Mechanisms.
Grabuschnig S; Bronkhorst AJ; Holdenrieder S; Rosales Rodriguez I; Schliep KP; Schwendenwein D; Ungerer V; Sensen CW
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33137955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
